OLHHA

OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) [1][2].

Product Specifications

CAS Number

[1258011-97-0]

UNSPSC

12352005

Hazard Statement

H225-H319

Target

Cannabinoid Receptor; PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/olhha.html

Solubility

10 mM in DMSO

Smiles

CCCCCCCC/C=C\CCCCCCCC(NC(C)CC1=CC=C(O)C(O)=C1)=O

Molecular Formula

C27H45NO3

Molecular Weight

431.65

Precautions

P210-P233-P240-P241-P242-P243-P264-P280-P303+P361+P353-P305+P351+P338-P370+P378-P403+P235-P501

References & Citations

[1]Alen F, et al. PPARα/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models. Biochem Pharmacol. 2018 Nov;157:235-243.|[2]Decara JM, et al. Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats. Dis Model Mech. 2015 Oct 1;8 (10) :1213-25.